View ValuationNewtopia 将来の成長Future 基準チェック /06現在、 Newtopiaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長19.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.お知らせ • Nov 10Newtopia Inc. to Report Q3, 2023 Results on Nov 16, 2023Newtopia Inc. announced that they will report Q3, 2023 results After-Market on Nov 16, 2023お知らせ • Oct 17Newtopia Inc. announced that it has received CAD 0.805 million in fundingOn October 16, 2023, the company announced that it has received CAD 425,000 in its second tranche. The securities issued pursuant to the offering are subject to a four month hold period that expires on February 14, 2024. The debentures issued in connection with this second tranche of the offering will mature on October 13, 2024. The company paid a finder's fee of CAD 1,800 and 15,652 non-transferable compensation options. Each compensation option is exercisable into one common share at CAD 0.115 per share, subject to adjustments in certain events, until October 13, 2025.お知らせ • Aug 05Newtopia Inc. to Report Q2, 2023 Results on Aug 09, 2023Newtopia Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023お知らせ • Jun 29Newtopia Inc. announced that it expects to receive CAD 0.5 million in fundingNewtopia Inc. announced a non-brokered private placement of 13% 50 units of Subordinated Non-Convertible debentures at a price of CAD 10,000 for the gross proceeds of CAD 0.5 million on June 27, 2023. Each unit will be comprised of CAD10,000 principal amount of subordinated and postponed secured non-convertible debentures of the company and bonus shares. In the event that the maximum amount of debentures are issued in connection with the offering, a maximum of 1,538,461 bonus shares will be issuable in connection with the offering. The debentures will mature on the date that is 24 months from the closing date of the offering and are secured by the assets of the Company and bear interest at a rate of 13% per annum payable quarterly in arrears in cash. The company will pay to the holders of the debentures an annual work and credit maintenance fee of 2% of the principal amount in cash. The debentures and the bonus shares to be issued pursuant to the offering, will be subject to a hold period of four months plus one day from the closing date. The offering is subject to approval by the TSXV and the consent of the company's Schedule I bank secured lender.お知らせ • Jun 03Newtopia Inc. announced that it has received CAD 0.0075 million in fundingNewtopia Inc. announced that it has received a private placement of 100,000 Shares at a price of CAD 0.075 for the gross proceeds of CAD 7,500 on June 1, 2023. The transaction included participation form individual investor McCauley. After the transaction McCauley owns and controls approximately 13,994,500 Shares and 1,000,000 common share purchase warrants representing 10.0% of the shares on a partially diluted basis.お知らせ • May 25Newtopia Inc. to Report Q1, 2023 Results on May 30, 2023Newtopia Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 30, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Newtopia は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NEWU.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20247-7-1-1N/A6/30/20248-6-2-2N/A3/31/20249-6-2-2N/A12/31/202310-7-2-2N/A9/30/202311-5-3-3N/A6/30/202311-6-4-4N/A3/31/202311-7-7-6N/A12/31/202211-8-7-6N/A9/30/202210-8-7-5N/A6/30/202211-7-7-5N/A3/31/202211-7-7-5N/A12/31/202110-8-8-6N/A9/30/202111-9-9-7N/A6/30/202110-9-9-8N/A3/31/202110-9-7-6N/A12/31/202011-8-5-5N/A9/30/202010-9-5-5N/A6/30/20209-9-5-5N/A3/31/20208-10-5-5N/A12/31/20196-10-6-6N/A9/30/20195-9-6-6N/A6/30/20195-8-5-5N/A3/31/20194-7-5-5N/A12/31/20183-6-5-5N/A12/31/20172-8N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NEWU.Fの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NEWU.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NEWU.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NEWU.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NEWU.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NEWU.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/30 20:36終値2025/12/31 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Newtopia Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Prasath PanduranganBloom Burton & Co.Andre UddinResearch Capital CorporationJustin KeywoodStifel Canada
お知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.
お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.
お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024
お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.
お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.
お知らせ • Nov 10Newtopia Inc. to Report Q3, 2023 Results on Nov 16, 2023Newtopia Inc. announced that they will report Q3, 2023 results After-Market on Nov 16, 2023
お知らせ • Oct 17Newtopia Inc. announced that it has received CAD 0.805 million in fundingOn October 16, 2023, the company announced that it has received CAD 425,000 in its second tranche. The securities issued pursuant to the offering are subject to a four month hold period that expires on February 14, 2024. The debentures issued in connection with this second tranche of the offering will mature on October 13, 2024. The company paid a finder's fee of CAD 1,800 and 15,652 non-transferable compensation options. Each compensation option is exercisable into one common share at CAD 0.115 per share, subject to adjustments in certain events, until October 13, 2025.
お知らせ • Aug 05Newtopia Inc. to Report Q2, 2023 Results on Aug 09, 2023Newtopia Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
お知らせ • Jun 29Newtopia Inc. announced that it expects to receive CAD 0.5 million in fundingNewtopia Inc. announced a non-brokered private placement of 13% 50 units of Subordinated Non-Convertible debentures at a price of CAD 10,000 for the gross proceeds of CAD 0.5 million on June 27, 2023. Each unit will be comprised of CAD10,000 principal amount of subordinated and postponed secured non-convertible debentures of the company and bonus shares. In the event that the maximum amount of debentures are issued in connection with the offering, a maximum of 1,538,461 bonus shares will be issuable in connection with the offering. The debentures will mature on the date that is 24 months from the closing date of the offering and are secured by the assets of the Company and bear interest at a rate of 13% per annum payable quarterly in arrears in cash. The company will pay to the holders of the debentures an annual work and credit maintenance fee of 2% of the principal amount in cash. The debentures and the bonus shares to be issued pursuant to the offering, will be subject to a hold period of four months plus one day from the closing date. The offering is subject to approval by the TSXV and the consent of the company's Schedule I bank secured lender.
お知らせ • Jun 03Newtopia Inc. announced that it has received CAD 0.0075 million in fundingNewtopia Inc. announced that it has received a private placement of 100,000 Shares at a price of CAD 0.075 for the gross proceeds of CAD 7,500 on June 1, 2023. The transaction included participation form individual investor McCauley. After the transaction McCauley owns and controls approximately 13,994,500 Shares and 1,000,000 common share purchase warrants representing 10.0% of the shares on a partially diluted basis.
お知らせ • May 25Newtopia Inc. to Report Q1, 2023 Results on May 30, 2023Newtopia Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 30, 2023